key: cord-0882479-sulzo1cw
authors: Dirlikov, Emilio; Jahun, Ibrahim; Odafe, Solomon F.; Obinna, Ogbanufe; Onyenuobi, Chibuzor; Ifunanya, Mgbakor; Efuntoye, Timothy A.; Tingir, Nguhemen; Ene, Uzoma; Fagbemi, Ayodele; Meribe, Chidozie; Bassey, Orji; Ayo, Adeola; Fagbamigbe, Omodele Johnson; Amafah, Joy; Bamidele, Moyosola; Alagi, Matthias; Oladipo, Ademola; Dalhatu, Ibrahim; Okoye, McPaul; Onotu, Dennis; Gwamna, Jerry; Abrams, William A.; Conner, Deborah A.; Nwaohiri, Anuli; Carpenter, Deborah; Ijeoma, Ugonna C.; Shah, Sarita; Tison, Laura I.; Shah, Minesh; Chun, Helen; Williams-Sherlock, Michelle; Boyd, Andrew T.; Bachanas, Pamela; Ikpeazu, Akudo; Aliyu, Gambo Gumel; Ellerbrock, Tedd; Swaminathan, Mahesh; FitzGibbon, Kathleen; Giambrone, Mark; Abutu, Andrew; Fellows, Ian; Murie, Lisa; Miller, David; Nnadozie, Obinna; Shiraishi, Ray; Thorsen, Viva; Adebayo, Opeyemi; Dakum, Patrick; Mensah, Charles; Mishara, Fadimatu; Kinmilola, Olupitan Olayemi; Pillatar, Benjamin; Okolo, Chukwu-Emeka; Verinumbe, Tarfa; Sambo, Yakubu; Yillong, Fidelis; Abe, Oluwaseun; Achor, Olaitan; Bashir, Musa; Bature, Stephen; Madina, Emily; Oyedelun, Bolanle; Bassey, Fabian; Effiong, Amana; Francis, Alimigbe; Magbadelo, Dorcas; Okolie, Charles; Oko, John Okpanachi; Olayiwola, Olanrewaju; Onu, Eugene; Onwuchekwa, Chukwudi; Obaje, Mikhail; Okwonkwo, Prosper; Usha, Thomas; Ejimkaraonye, Evans; Achebe, Chiagozie; Adebajo, Sylvia; Alonge, Johnson; Asiozi, Moses; Attah, Nelson; Musei, Nnabundo; Onyekachi, Prosper; Stafford, Kristen A.
title: Rapid Scale-up of an Antiretroviral Therapy Program Before and During the COVID-19 Pandemic — Nine States, Nigeria, March 31, 2019–September 30, 2020
date: 2021-03-26
journal: MMWR Morb Mortal Wkly Rep
DOI: 10.15585/mmwr.mm7012a3
sha: a6aa359118bcd35b283a02f7a1123298ebfeb8b7
doc_id: 882479
cord_uid: sulzo1cw

In 2018, an estimated 1.8 million persons living in Nigeria had HIV infection (1.3% of the total population), including 1.1 million (64%) who were receiving antiretroviral therapy (ART) (1). Effective ART reduces morbidity and mortality rates among persons with HIV infection and prevents HIV transmission once viral load is suppressed to undetectable levels (2,3). In April 2019, through the U.S. President's Emergency Plan for AIDS Relief (PEPFAR),* CDC launched an 18-month ART Surge program in nine Nigerian states to rapidly increase the number of persons with HIV infection receiving ART. CDC analyzed programmatic data gathered during March 31, 2019-September 30, 2020, to describe the ART Surge program's progress on case finding, ART initiation, patient retention, and ART Surge program growth. Overall, the weekly number of newly identified persons with HIV infection who initiated ART increased approximately eightfold, from 587 (week ending May 4, 2019) to 5,329 (week ending September 26, 2020). The ART Surge program resulted in 208,202 more HIV-infected persons receiving PEPFAR-supported ART despite the COVID-19 pandemic (97,387 more persons during March 31, 2019-March 31, 2020 and an additional 110,815 persons during April 2020-September 2020). Comprehensive, data-guided, locally adapted interventions and the use of incident command structures can help increase the number of persons with HIV infection who receive ART, reducing HIV-related morbidity and mortality as well as decreasing HIV transmission.

In 2018, an estimated 1.8 million persons living in Nigeria had HIV infection (1.3% of the total population), including 1.1 million (64%) who were receiving antiretroviral therapy (ART) (1) . Effective ART reduces morbidity and mortality rates among persons with HIV infection and prevents HIV transmission once viral load is suppressed to undetectable levels (2, 3) . In April 2019, through the U.S. President's Emergency Plan for AIDS Relief (PEPFAR),* CDC launched an 18-month ART Surge program in nine Nigerian states to rapidly increase the number of persons with HIV infection receiving ART. CDC analyzed programmatic data gathered during March 31, 2019-September 30, 2020, to describe the ART Surge program's progress on case finding, ART initiation, patient retention, and ART Surge program growth. Overall, the weekly number of newly identified persons with HIV infection who initiated ART increased approximately eightfold, from 587 (week ending May 4, 2019) to 5,329 (week ending September 26, 2020). The ART Surge program resulted in 208,202 more HIV-infected persons receiving PEPFAR-supported ART despite the COVID-19 pandemic (97,387 more persons during March 31, 2019-March 31, 2020 and an additional 110,815 persons during April 2020-September 2020). Comprehensive, data-guided, locally adapted interventions and the use of incident command structures can help increase the number of persons with HIV infection who receive ART, reducing HIV-related morbidity and mortality as well as decreasing HIV transmission.

In April 2019, CDC launched an 18-month ART Surge program to rapidly increase the number of persons with HIV infection receiving ART. † CDC and its four implementing partners § established incident command structures to manage operations leadership. ¶ Implementing partners reported weekly site-level data, beginning April 28, 2019. Data were distributed broadly to critical stakeholders (e.g., CDC Nigeria country office, U.S. CDC headquarters, and implementing partners) through an Excel-based dashboard, which was used to analyze data and adapt operations. Interstate learning was facilitated through weekly videoconferences among stakeholders and site visits.

Weekly ART Surge programmatic data and quarterly PEPFAR Monitoring and Evaluation Reporting data,** was analyzed to assess ART Surge progress across four areas: 1) case findings † † measured by the weekly number of positive test results ¶ Since August 2019, senior leaders from the U.S. Mission Nigeria (including the ambassador, deputy chief of mission, and consul general), and country directors for the U.S. CDC and the U.S. Agency for International Development, engaged state governors, religious and traditional leaders, and civil society groups. Engagement activities included outreach to destigmatize HIV, advocacy to eliminate user fees for persons seeking HIV treatment, and requests for assistance with the provision of rapid test kits. Diplomatic engagement enlisted state governors in Benue, Imo, Lagos, Nasarawa, and Rivers to support ART Surge activities, resulting in increased health resources for and knowledge of the CDC ART Surge program. ** Weekly programmatic data reporting began the week ending on May 4, 2019.

Reporting weeks end on Saturdays. All PEPFAR-supported countries are required to report Monitoring and Evaluation Reporting data quarterly. † † Case finding interventions included prioritization of substate geographic units with the largest estimated ART coverage gap; enhanced use of a nationally validated risk stratification tool to screen persons with higher risk for HIV infection; engagement of core community-based organizations; targeted community testing; and programming based on weekly reported data. and positivity rate (i.e., proportion of tests that were positive); 2) ART initiation, measured by the weekly number of newly identified persons with HIV infection who initiated ART and the rates of linkage to ART, using a proxy indicator calculated as the number (Table) . The annualized (March 2019-March 2020) proxy retention indicator was 99% overall, and the state proxy retention indicator ranged from 88% in Lagos to 117% in Gombe.*** ART Surge activities were affected by the COVID-19 pandemic during March-May 2020, † † † with fewer tests conducted, fewer positive test results, and fewer newly identified persons with HIV infection who initiated ART. Following Nigeria Centre for Disease Control guidelines, the ART Surge program implemented COVID-19 mitigation measures, including provision of face masks for staff members, enhanced hand hygiene by staff members and clients during clinical visits, and physical distancing measures (e.g., staggered clinical appointments, 2-meter spacing between seating). Given limitations in facility-based services, community-based activities were increased through mobile teams, toward strengthened case finding, ART initiation, and patient retention. By May 16, 2020, ART Surge activities returned to prepandemic levels (i.e., those before March 21, 2020) and continued to increase (Table) . (1). In addition, the ART Surge program's incident command structures provided flexible management of operations, and weekly data disseminated through a user-friendly dashboard allowed for data-guided, locally adapted interventions and improved accountability. Collaboration among ART Surge states facilitated interstate learning and helped disseminate successful interventions to achieve broader implementation. Finally, diplomatic engagement with governors and local leaders helped combat HIV stigma, supported the elimination of user fees (e.g., registration fees and folder fees), and assisted with the provision of rapid test kits from local stakeholders. Despite this progress, many persons with HIV infection in Nigeria remain unaware of their status and are not receiving ART (1) . Additional interventions could help improve case finding, ART initiation, and patient retention. For example, in October 2020, through PEPFAR, CDC expanded the ART Surge program strategies to nine additional states. § § § Data § § § In addition to the nine ART Surge states (Benue, Delta, Enugu, Federal Capital Territory, Gombe, Imo, Lagos, Nasarawa, and Rivers), in October 2020, through PEPFAR, CDC expanded the ART Surge program strategy to the following nine states: Ekiti, Kaduna, Katsina, Kogi, Ogun, Ondo, Osun, Oyo, and Plateau.

analysis that supports programmatic activities, such as case finding and rapid linkage to treatment, might help identify more persons with HIV infection who are not receiving ART, including female sex workers and men who have sex with men, who are among the populations at higher risk for infection. As more persons with HIV infection receive ART, adherence, patient retention, and viral load suppression remain critical. In addition, preventive measures to minimize losses and reengage persons with HIV infection who miss appointments, or have dropped out of care, are important to reach and maintain ART coverage targets. Site-level improvements adapted to local needs and preferences are also important. The findings in this report are subject to at least four limitations. First, despite continual PEPFAR data quality assurance activities, data quality might be affected by reporting challenges (e.g., site-level electricity or Internet outages preventing data transmission). Second, newly identified patients with HIV infection were categorized by client self-reporting; therefore, the actual proportion of newly identified persons with HIV infection who initiated ART is unknown. Third, proxy indicators derived from aggregate program data were used to evaluate

Newly identi ed persons with HIV infection who initiated ART Linkage to ART (proxy) 4 18 1 15 29 13 27 10 24 7 21 5 19 2 16 30 14 28 11 25 8 22 7 21 4 18 2 16 30 13 27 11 25 8 22 5 ART initiation and patient retention, which might vary from patient-level analysis. Finally, persons with HIV infection can access health services at any site, regardless of state of residence; therefore, some persons might have been counted more than once, which limited direct assessment of ART coverage.

Despite the challenges of the COVID-19 pandemic, CDC's ART Surge program has accelerated progress toward HIV epidemic control in Nigeria, which is aligned with UNAIDS targets (5) . Comprehensive, data-guided, locally adapted interventions and incident command structures can help increase and retain the number of persons with HIV infection who receive ART, reducing HIV-related morbidity and mortality as well as decreasing HIV transmission.

Biosecurity and Maryland Global Initiatives Corporation

Center for Global Health, CDC; 2 Division of Global HIV &TB, Center for Global Health, CDC Nigeria; 3 National AIDS and STIs Control Programme

Federal Ministry of Health

PARTNER Study Group. Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy

HPTN 052 Study Team. Antiretroviral therapy for the prevention of HIV-1 transmission

Joint United Nations Programme on HIV/AIDS. 90-90-90: an ambitious treatment target to help end the AIDS epidemic

Nigerian federal and state governments; state-based consortium; site staff members; implementing partners. 

All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.